2

1

global analysis of SARS-CoV-2 genomic epidemiology

A validated cloud-based genomic platform for co-ordinated, expedient

3 Authors

4 Daniel Amoako,¹ Nguyen To Anh,² Jasmine Bastable,³ Marc Brouard,⁴ Constanza Campano Romero,⁵ Andres Castillo Ramirez,⁵ Bede Constantinides,⁴ Derrick W. Crook,^{3,4} Phan 5 6 Manh Cuong,⁶ Moussa Moise Diagne,⁷ Amadou Diallo,⁷ Nguyen Thanh Dung,⁸ Laura 7 Dunn,³ Le Van Duyet,⁶ Josie Everatt,¹ Katherine Fletcher,⁴ Philip W. Fowler,⁴ Mailie Gail,⁹ 8 Jessica Gentry,³ Saheer Gharbia,¹⁰ Hospital for Tropical Diseases SARS-CoV-2 testing 9 team,⁸ Nguyen Thi Thu Hong,² Martin Hunt,^{4,12} Zam Iqbal,^{4,12} Katie Jeffery,³ Dikeledi Kekana,¹ Thomas Kesteman,² Jeff Knaggs,^{4,12} Marcela Lopes Alves,⁴ Dinh Nguyen Huy 10 11 Man,⁸ Amy J. Mathers,¹¹ Nghiem My Ngoc,⁸ Sarah Oakley,³ Hardik Parikh,¹¹ Tim E.A. Peto,^{3,4} Phuong Quan,⁴ Marcelo Rojas Herrera,⁵ Nicholas Sanderson,⁴ Vitali Sintchenko,⁹ 12 Jeremy Swann,⁴ Junko Takata,^{3,4} Nguyen Thi Tam,² Le Van Tan,² Pham Ngoc Thach,⁶ 13 Ndeve Marieme Top,⁷ Nguyen Thu Trang,² Van Dinh Trang,⁶ Robert Turner,⁴ H. Rogier 14 van Doorn,² Anne von Gottberg,^{1,13} Jeremy Westhead,⁴ Nicole Wolter,^{1,13} Bernadette C. 15 Young^{3,4} 16

17

18 Author Affiliations

19 1. The National Institute for Communicable Diseases (NICD), a division of the

20 National Health Laboratory Service, Johannesburg, Republic of South Africa

21 2. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

22 3. Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

23 4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

24 5. El Instituto de Salud Pública de Chile, Santiago, Chile

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25	6. National Hospital for Tropical Diseases, Hanoi, Vietnam
26	7. The Institut Pasteur de Dakar, Dakar, Senegal
27	8. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
28	9. Microbial Genomics Reference Laboratory, Institute of Clinical Pathology and
29	Medical Research, New South Wales Health Pathology, Sydney, Australia
30	10. Genomic Surveillance Unit, The Wellcome Sanger Institute, Hinxton, United
31	Kingdom
32	11. Division of Infectious Diseases, School of Medicine, University of Virginia,
33	Charlottesville, United States of America
34	12. European Bioinformatics Institute, Hinxton, United Kingdom
35	13. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
36	Africa
37	
38	Corresponding author: Bernadette Young (<u>bernadette.young@ndm.ox.ac.uk</u>), Nuffield
39	Department of Medicine, University of Oxford, Oxford, OX3 9DU, 01865 220856.
40	
41	Running title: Coordinated cloud-based genome analysis for SARS-CoV-2
42	
43	Keywords: COVID-19, SARS-CoV-2, public health genomics, bioinformatics
44	
45	Article Summary Line: A cross-sectional study of SARS-CoV-2 sequencing demonstrates
46	that cloud-based sequencing analysis has the power to relieve bioinformatic bottlenecks,
47	and facilitate collaboration in pathogen surveillance to enhance pandemic preparedness.

48 Abstract

49 Background

50 Viral sequencing has made critical contributions to our understanding of and response to 51 the COVID-19 pandemic, but sequencing capacity and bioinformatic expertise remain 52 limited in many settings. This proof-of-principle study aimed to demonstrate the utility 53 of a cloud-based sequencing analysis pipeline, the Tiled Amplicon Pipeline (TAP), for 54 rapid and collaborative SARS-CoV-2 sequencing across seven globally distributed sites.

55

56 Methods

In this cross-sectional study from July to August 2022, seven sites submitted all SARS-CoV-2 sequence data generated over a two-week period to our cloud platform. No patient identifying information was uploaded, and human reads were removed prior to upload to the cloud. Users could opt in to share sample information with collaborators via a tagging system. The pipeline performed sequence assembly, lineage identification and relatedness analysis.

63

64 **Results**

Seven sites contributed 5,432 sequences, of which 5,342 (98.3%) were from clinical samples and 90 (1.7%) were controls. Of the clinical samples that were correctly assembled, 3,439/4,179 (82.3%) had sufficient coverage for lineage assignment. Omicron lineages dominated, with BA.5, BA.4 and BA.2 comprising the vast majority, consistent with contemporary epidemiological observations at the time. Phylogenetic analysis demonstrated low diversity within lineages, and genotypically identical or highly similar sequences were recovered from globally disparate sites.

72

73 **Conclusions**

- 74 A cloud-based analysis platform like TAP addresses bioinformatic bottlenecks and
- 75 facilitates collaboration in pathogen surveillance, enhancing epidemic and pandemic
- 76 preparedness.

77 Introduction

78 Viral genome sequencing has proven pivotal to understanding the evolution of the SARS-79 CoV-2 virus during the COVID-19 pandemic and in shaping the public health response. 80 International genomic surveillance and data sharing initiatives have together made it 81 possible to track the emergence of variants globally [1], to demonstrate the impact of 82 travel restrictions on viral dynamics across continents [2] or within countries [3, 4], and 83 to identify transmission routes within hospitals [5]. Successive waves of infection driven 84 by new variants showed that rapidly detecting new lineages is critical for understanding 85 disease epidemiology and guiding subsequent public health responses [6], as well as 86 informing the development of vaccines and therapeutics such as neutralising antibodies 87 [7-9].

88

89 However, the pandemic also highlighted marked global variability in sequencing capacity 90 and cost [10], with much of the SARS-CoV-2 sequencing undertaken at centralised 91 reference laboratories [11]. Several important challenges remain in expanding genomic surveillance, including access to sequencing technology, availability of bioinformatic 92 93 expertise, and interpretability of results generated using a plethora of different wet lab 94 and bioinformatics protocols [12-14]. There is a need for accessible genomic surveillance 95 infrastructure that can be used by researchers and clinicians from any location, to deliver 96 an up-to-date global perspective of viral evolution.

97

98 One solution to both the shortage of bioinformatic expertise and the lack of global 99 interpretability of results is web-accessible analysis infrastructure [15]. The Global 100 Pathogen Analysis Service (GPAS) was rapidly set up in 2021 in response to the COVID-101 19 pandemic by the University of Oxford as a cloud-based, globally accessible web

102 platform. GPAS provided fast and secure access to a comprehensive SARS-CoV-2 genomic 103 analysis pipeline, delivering genome assembly, variant calling and lineage classification 104 from raw sequence data. Users retained control of their data but could opt in to share 105 their data to facilitate comparisons in a wider context, empowering laboratories to 106 control their own analysis. GPAS was validated to UKAS ISO 15189:2012 standards in a 107 UK tertiary hospital clinical microbiology laboratory, and was commissioned by the UK 108 Health Security Agency for over a year to support Pillar 1 national surveillance and 109 various clinical trials. GPAS provided proof-of-principle that standard microbiology 110 laboratories without bioinformatics expertise can generate outputs for local surveillance 111 and automatically submit sequences to public repositories.

112

In 2024, GPAS was upgraded as the Tiled Amplicon Pipeline (TAP) with major 113 114 enhancements to several software components. Since January 2025 TAP has been deployed as the SARS-CoV-2 pipeline on EIT Pathogena (version 1.2.0), a multi-pipeline 115 116 genomic pathogen analysis platform that is free of charge for users in low- and middleincome countries and accessible in all settings with internet access [16]. This service 117 118 demonstrates the potential of cloud-based platforms to overcome barriers to 119 democratising effective genomic surveillance, making advanced genomic analysis 120 available to resource-limited laboratories.

121

122 In this paper, we report the results of a collaborative, cross-sectional SARS-CoV-2 123 sequencing study across seven globally distributed sites, which demonstrate the utility 124 of a cloud-based sequencing platform in providing a quality assured, rapid, and 125 integrated global snapshot of viral diversity. We further describe the components of the

- 126 pipeline and discuss its potential for rapid adaptation in response to future viral
- 127 pandemics.

128

129 Methods

130 **Pipeline development**

131 TAP was deployed to a cloud platform and controlled via a Command Line Interface (CLI) 132 tool. Full methodology is described in the Appendix (Supplementary Appendix A). At upload, a universally unique identifier (UUID) is generated and assigned to each sample. 133 The mapping between the UUID and the user's sample identifier is downloaded and only 134 135 held by the user, and FASTQ header lines are also truncated, ensuring that no potentially 136 personally identifiable information is transmitted to the cloud platform. Tight access 137 control to data applies within TAP, and by default data is not shared with other users 138 unless explicitly authorised by the data owners.

139

140 Following FASTQ file upload to the cloud, processing commences automatically with no further user input required. Any reads mapping to the human genome are first removed 141 142 [17], reducing the risk of any human reads being retained. Genome assembly is 143 performed by an amplicon-aware genome assembly tool Viridian v1.3.1 [18], which 144 scaffolds per-amplicon *de novo* assemblies into a single whole genome consensus 145 assembly in FASTA format. Viridian was configured to use the SARS-CoV-2 reference 146 genome Wuhan-Hu-1 (MN908947.3) for assembly and variant calling [19], and a library 147 of seven amplicon primer schemes (AmpliSeq v1; ARTIC versions 3, 4.1, 5.3.2 (400), 5.2.0 148 (1200); Midnight 1200; VarSkip v1a-2b). When a primer scheme is not specified by the 149 user, Viridan can automatically infer the most likely primer scheme from within its 150 library.

151

After assembly, amino acid mutations are identified using Nextclade [20], and Pango
lineages are assigned with Pangolin version 4.3.1 [21]. Aligned sequences are compared

154 using a novel algorithm, FindNeighbour5, which identifies single nucleotide variant 155 (SNV) distances between sequences without conflicting variant calls (0 SNVs) as well as 156 those differing by one, two and three SNVs [22, 23]. The main outputs from the pipeline are presented in an access-restricted user interface portal and downloadable as a 157 158 summary file containing the lineage assignment, a list of related samples (according to 159 permissions), and metrics of the genome assembly (e.g. coverage, mean depth, amplicon 160 dropouts, etc). Detailed intermediate files such as VCF or FASTA files are also available 161 for download.

162

163 **Pipeline validation**

164 GPAS was validated for both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms in 2021, using various datasets including a 'truth set' of cultured 165 SARS-CoV-2 samples sequenced with multiple platforms and library preparations, 166 annotated with manually curated variant calls (described in further detail in [18] and 167 168 [24]), in addition to community samples collected in Northumbria, UK. Overall, GPAS 169 showed negligible adjusted false call rates (less than 1/100,000 nucleotides) with respect 170 to the 'truth set', and had high concordance (less than 1.9/1,000,000 discordant events) 171 with the ARTIC assembly pipeline in use at the time.

172

TAP was subsequently validated against the same 'truth set' of cultured SARS-CoV-2 samples, which achieved 100% concordance with expected Pango lineages using the same Pangolin version. Concordance of TAP and GPAS was further compared using data from the current study, which showed 99.4% concordance in lineage calls (using the same Pangolin and Viridian versions), and nucleotide call discordance of 0.59/1,000,000

sites. Further details of the validation and comparison processes are described inSupplementary Appendix B.

180

181 Sample frame, sequencing, and upload

182 Between July and August 2022, seven sequencing centres participated in a two-week 183 sequencing pilot across seven countries: Senegal; Chile; South Africa; New South Wales 184 (NSW), Australia; Vietnam; United Kingdom (UK); and Virginia, United States (USA). 185 Centres were either accredited clinical microbiology or public health laboratories. All 186 clinical samples in which SARS-CoV-2 was detected were eligible for inclusion and 187 underwent in-house genomic sequencing at participating sites, with no more than one 188 submission from an individual patient. Sequencing platform (either Illumina or ONT) and 189 primer schemes were chosen by participating sites, who followed their established 190 sequencing protocols.

191

Raw sequences were uploaded in FASTQ format to GPAS, the working name of the 192 193 pipeline at the time, along with limited associated metadata (sample name, instrument 194 platform, sample type [clinical or control], collection date, and country). Submitting sites 195 verified the run quality reports of each sequencing batch including a review of positive 196 and negative controls, and batches were passed or failed accordingly. All passed samples 197 were tagged to release them to the shared data pool for subsequent aggregate analysis; 198 explicit permission was given from all collaborators to configure data access controls 199 such that all submitters could access and view each other's sequences, metadata, and 200 analytical outputs. For this study, primer scheme information was not provided by the 201 user, and automatic detection of primer scheme was enabled. All sequences were

202 uploaded to the European Nucleotide Archive (project accession: PRJEB70597) at the203 time of the study.

204

205 Data analysis

206 FASTQ files from the study were redownloaded from the ENA and run through EIT

- 207 Pathogena (version 1.2.0 pre-release) on 6th November 2024. A maximum likelihood
- 208 phylogeny of aligned sequences was constructed for the three largest Pango lineages in
- 209 the sample set (BA.5, BA.4 and BA.2) using IQTree version 2.3.6, assuming a general time
- 210 reversible nucleotide substitution model with gamma rate heterogeneity, and using the
- 211 consensus tree from 1000 ultrafast bootstrapping [25]. All other analyses were
- conducted in RStudio version 2023.06.0+421.

213 **Results**

214 **Primer scheme detection**

215 5,432 sequences were shared across seven sites (Supplementary Table 1), with date of 216 collection ranging from April to July 2022. Of submitted samples, 90 (1.7%) were controls 217 and 5,342 (98.3%) were clinical samples. Primer schemes were successfully auto-218 detected for 4,238/5,432 (78.0%) of samples, but were incorrectly inferred for all 219 1,194/5,432 (22.0%) samples from NSW, Australia which appropriately failed the 220 Viridian guality control threshold for assembly. Further investigation showed that these 221 samples were sequenced using a bespoke primer scheme that is not included in the 222 current Viridian library, and these samples were excluded from further analysis.

223

224 Aggregate analysis of global genetic epidemiology

Among the clinical samples included in the analysis, 3,751/4,179 (89.8%) were assembled with at least 70% genome coverage (Table 1). 3,439/4,179 (82.3%) clinical samples were assembled with sufficient coverage and post-assembly quality to be assigned a lineage (Table 2). 3,412/3,439 (99.2%) were Omicron variants, with BA.5, BA.4 and BA.2 being the most common. A small number of Delta variant sequences were identified (0.4%, 15/3,439), all of which were collected prior to July 2022.

231

232

- 233
- 234
- 235
- 236

medRxiv preprint doi: https://doi.org/10.1101/2023.11.27.23298986; this version posted January 23, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .
--

Centre	Submitted samples	Controls	<50% coverage*	50-70% coverage	>70% coverage	Earliest sample	Latest sample
Senegal	197	0	9	10	178	13th July 2022	20th July 2022
Chile	1205	20	4	6	1175	16th June 2022	22nd July 2022
South Africa	202	0	7	6	189	17th May 2022	24th June 2022
Vietnam	316	3	14	7	292	1st April 2022	14th July 2022
United Kingdom	1818	36	280	85	1417	12th July 2022	26th July 2022
Virginia, USA	500	0	0	0	500	7th June 2022	28th June 2022
Total	4238	59	314	114	3751		

237

238 **Table 1: Samples submitted by study centre, with date of collection and genome coverage.** Earliest

and latest sample dates exclude controls.

240 * includes samples that could not be assembled

	Omic	ron						Delta	Alpha	Other*	Total
Contro	BA.1	BA.2	BA.4	BA.5 a	nd rela	ated		AY.5,	B.1.1.7		
Centre				BA.5	BE	BF	Other (BG, BK)	AY.57, B.1.617.2			
Senegal	0	17	24	28	2	12	0	0	0	0	83
Chile	0	136	570	302	26	63	1	0	0	5	1103
South Africa	0	3	82	77	8	3	0	0	0	3	176
Vietnam	2	228	0	6	0	0	0	15	0	0	251
United Kingdom	2	57	165	864	137	111	0	0	1	2	1339
Virginia, USA	0	289	89	84	12	9	3	0	0	1	487
Total	4	730	930	1361	185	198	4	15	1	11	3,439

241

Table 2: SARS-CoV-2 lineage of samples by study centre (where a lineage was assigned by Pangolin).

243 * Other includes: P.1, P.1.2, A, A.2.2, B.1, B.1.429, B.28, C.37, DE.1, XAM, XAN, XAS, XAZ, XBA, P.2

244

245 Global mixing across multiple Omicron lineages

For clinical samples collected between 1st June 2022 and 31st July 2022, the proportion

of samples assigned to the different Omicron sub-lineages varied substantially by study

site (Figure 1). Each of BA.2, BA.4 or BA.5 dominated (constituted >50% of samples from)

at least one site, while in Senegal no single lineage dominated, and BA.4 and BA.5 were







- 252
- 253

Figure 1: Omicron sub-lineages by study site. Proportion of samples assigned to Omicron sub-lineages
within each study site, where collection date was in June or July 2022.

256

Maximum likelihood phylogenies for each of the three most common lineages revealed global mixing of Omicron lineages (Figure 2). There were no examples of sub-lineages being completely geographically restricted to one site; one sub-lineage of BA.4 was found predominantly in Chile, but an example of this sub-lineage was also identified in the United Kingdom.



263

Figure 2: Maximum likelihood phylogeny of isolates from each major lineage (BA.2, BA.4, BA.5). Final branches are coloured according to the centre in which they

were sequenced.

266 For all three major lineages, there was evidence of genotypically identical (SNV = 0) and 267 highly related (SNV \leq 3) samples being found in different study sites, with increasing 268 dispersal with higher SNV thresholds (Figure 3; Supplementary Table 2). The greatest 269 dispersal was seen in the BA.4 lineage: of 358 samples with another genotypically 270 identical sample, only 69.6% (249/358) were from the same site, with the rest 271 distributed across the remaining sites. In addition, only 10.3% (96/930) of BA.4 and 272 12.7% (173/1,361) of BA.5 samples did not have any related samples (SNV \leq 3) in the 273 shared pool, in contrast to BA.2 samples where 51.8% (378/730) samples had a related 274 sample in the shared pool.

275



276

Figure 3: Percentage of unique samples for which all related samples were found only at the same site, at

278 each genotypic relatedness (SNV) threshold.

279

280 **Cloud processing time and performance**

At the time of the study, cloud processing performance on GPAS was measured by time 281 282 elapsed between upload and completion of analysis. Median cloud processing time per sample was 30.6 minutes (IQR: 13.1 – 69.9); variability was observed, with several 283 284 batches from Australia, UK and USA taking longer than 1000 minutes (Supplementary Figure 1). These were caused by either a data centre outage during an extreme heat event 285 286 in the UK, or as a result of a software update prematurely applied to the upload portal, 287 which was promptly resolved by improvements in the client side CLI software. Other data 288 upload issues were identified and addressed case-by-case, including metadata file 289 formatting errors, the availability of upload clients compatible with all required 290 operating systems, and user interface display errors preventing batch release.

291

292 In TAP, median cloud processing time per sample for a typical batch of 100 was 14.5 293 minutes (IQR: 13.8 – 15.0) for Illumina and 15.6 minutes (IQR: 15.2 – 16.7) for ONT; due 294 to parallelisation, processing a single batch of 100 samples was achievable in 19.7 295 minutes (Illumina) and 20.4 minutes (ONT) (Supplementary Figure 2). Processing all 296 5,432 samples took 766 minutes (12.7 hours). CPU time per sample is approximately 3 297 minutes (noting that this occurs in parallel, i.e. 2 CPUs working for 4 minutes would be 298 reported as 8 minutes CPU time by the workflow manager, despite only taking 4 299 minutes); majority of analysis time is associated with other pipeline activities including 300 network file transfers or reading data from disk into memory. Peak RAM usage for typical 301 use of the pipeline was approximately 5GB.

302 **Discussion**

303 This pilot study demonstrates the potential of globally synchronous data processing and 304 analysis in informing public health, through a unified protocol of genome assembly, 305 variant calling and relatedness analysis. The aggregated analysis from this study 306 conforms to contemporary observations of SARS-CoV-2 genetic epidemiology at the time [26-28], and demonstrates cosmopolitan global mixing of Omicron lineages between 307 308 study sites. Even a BA.4 sub-lineage found almost exclusively in Chile was not completely 309 restricted to that site and could be identified in a geographically distant site (UK). 310 Similarly, between 15.3% to 30.4% of genotypically identical (SNV=0) sequences were 311 identified in different countries over the same two-month period. Such mixing of lineages 312 likely reflects the relaxation of travel restrictions in the participating sites at the time of 313 the study, and captures the rapid global dispersal of Omicron with successive selective 314 sweeps of new lineages over short time scales [29]. These observations highlight the potential of a cloud-based sequencing pipeline in facilitating data sharing and generating 315 316 co-ordinated insights that could inform real-time decision-making.

317

While automatic primer scheme detection was used for this study, our results show the 318 319 limitation in this approach, with one centre using a custom scheme not contained in the 320 current Viridian primer scheme library. With viral evolution, it is inevitable that new 321 and/or modified primer schemes will continue to be developed to maintain sequencing 322 coverage of an evolving target genome. Viridian has the capability to accommodate 323 custom primer schemes when provided with a suitable scheme definition in browser extensible data (BED) format. This capability will form the basis of future pipeline 324 iterations and will allow the pipeline to pivot in future to assemble other viruses beyond 325 326 SARS-CoV-2 that use tiled amplicon sequencing. In turn, this ability to rapidly adapt

existing infrastructure for emerging threats, rather than build bespoke solutions from
scratch each time, supports a proactive and 'Always On' approach to pandemic
preparedness [30].

330

331 Our study is limited by the opportunistic sampling frame used and is likely to be 332 geographically incomplete, with a preponderance for countries that have historically 333 contributed more to global sequencing efforts. Similarly, our study has the limitation of 334 lacking longitudinal data on how these findings changed over time. Despite these 335 shortcomings, we have demonstrated how even a simply structured sampling across time 336 and space is still well placed to rapidly identify replacement by new lineages. Such 337 limitations in sampling frame diversity and global disparity in sequencing volume were 338 reflected during the pandemic itself: sequencing efforts in high-income countries were 339 up to ten-fold higher than that achieved in low- and middle-income countries during the 340 first two years [11], and data was not collected evenly over the course of pandemic. Well 341 designed, suitably powered, and representative sampling is a key part of pandemic preparedness planning, as exemplified by a cohort design in the UK [27]. 342

343

The world is now better prepared to urgently initiate genomic pathogen surveillance. The 344 345 available sequencing platform capacity is much improved, and the achievements of global data aggregation (as illustrated by INSDC, GISAID and Pathoplexus databases) have 346 347 alleviated a major obstacle to effective genomic surveillance and data sharing. In turn, the 348 integration of genomic data with disease manifestation and severity data would enable 349 the ready investigation of associations between genomic variation and clinical outcome 350 as suggested by others [31], and facilitate predictive modelling for anticipating the course 351 of future epidemics [32].

352

353 A remaining obstacle, especially in low-resource settings, is establishing local turnkey 354 bioinformatics to ensure standardised, quality-assured outputs that do not depend on inhouse bioinformatics expertise. In TAP, we have developed an exemplar of such a cloud-355 356 based service, with simple ingestion of local sequence data and flexible privacy 357 protections for data sharing to facilitate local or international comparative analyses. 358 While factors such as internet bandwidth may limit real-world performance, TAP is 359 capable of rapid parallel data processing, with a run time of 15 minutes per sample and 360 20 minutes in total for a batch of 100 typical SARS-CoV-2 genomes. The EIT Pathogena 361 platform ensures sustainability of technical and infrastructural support to the pipeline 362 and is currently freely available to low- and middle-income countries, supporting long-363 term use across research, clinical, or surveillance settings. Such a service, in turn, contributes to the growing global landscape of genomic data sharing that will underpin 364 365 future pandemic preparedness.

366

367 **Conclusions**

368 The COVID-19 pandemic has demonstrated the multiple ways in which viral sequencing 369 can inform pandemic responses, but also the inequitable distribution of resources and 370 capabilities. A service such as TAP contributes to the democratisation of genomics, 371 enabling researchers and laboratories, regardless of their location or bioinformatics 372 expertise, to participate actively in global surveillance efforts. By providing accessible 373 and user-friendly tools for sequence assembly, lineage assignment, and data sharing, it 374 promotes inclusive collaboration, harmonises data, and ultimately enhances pandemic preparedness. 375

376 Author contributions

- 377 Study conceptualisation: BCY, DWC
- 378 Study design: BCY, DWC
- 379 Software building and computational infrastructure: MB, BC, MH, ZI, PWF, JK, MLA, NS,
- 380 JS, RT, JW
- 381 Data collection: DA, NTA, JB, CCR, ACR, PMC, MMD, AD, NTD, LD, LVD, JE, KF, MG, JG, SG,
- 382 Hospital for Tropical Diseases SARS-CoV-2 testing team, NTTH, KJ, DK, TK, DNHM, AJM,
- 383 NMN, SO, HP, MRH, VS, NTTa, LVT, PNT, NMT, NTTr, VDT, HRVD, AvG, NW
- 384 Data analysis: JT, BCY, BC, TEAP, PQ
- 385 Manuscript writing: JT, BCY, BC
- 386 Manuscript editing and review: all authors
- 387

388 Funding statement

GPAS is a non-profit organisation, and GPAS cloud infrastructure was supported by a donation from Oracle Corporation. For this study, all GPAS services were offered free of charge to all sites, and staff costs for the analysis team were met by the University of Oxford, with support from the National institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). TAP is deployed on the EIT Pathogena platform, funded by the Ellison Institute of Technology Oxford. EIT Pathogena is free at the point of use for users in low- and middle-income countries.

396

Sequencing activities for NICD are supported by a conditional grant from the South
African National Department of Health as part of the emergency COVID-19 response; a
cooperative agreement between the National Institute for Communicable Diseases of the
National Health Laboratory Service and the United States Centers for Disease Control and

401 Prevention (NU51IP000930); the South African Medical Research Council (SAMRC) with 402 funds received from the South African Department of Science and Innovation; the African 403 Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and 404 Prevention through a sub-award from the Bill and Melinda Gates Foundation grant 405 number INV-018978; Africa PGI, the UK Foreign, Commonwealth and Development Office 406 and Wellcome (Grant no 221003/Z/20/Z); and the Department of Health and Social 407 Care's Fleming Fund using UK aid. NICD sequencing was also supported by The 408 Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the Centers for 409 Disease Control and Prevention (CDC) and the COVID International Task Force (ITF) 410 funds through the CDC under the terms of a subcontract with the African Field 411 Epidemiology Network (AFENET) AF-NICD-001/2021.

412

Genomic surveillance conducted in Vietnam was supported by the Wellcome Trust
(222574/Z/21/Z). L.V.T. is supported by the Wellcome Trust of Great Britain
(204904/Z/16/Z and 226120/Z/22/Z).

416

417 **Ethical statement**

SARS-CoV-2 sequencing was performed for public health surveillance and ethical 418 419 approval for secondary analysis was not required. This determination was reviewed by 420 the University of Oxford Joint Research Office. No patient identifying information was shared as part of this study. Sample identifiers remain with the submitter, and are never 421 kept on GPAS/TAP, or shared with other users. GPAS/TAP generates identifiers for each 422 423 sequence and writes a file linking anonymised ID to the submitted identifiers. Only the user submitting sequence data has access to these records. The GPAS/TAP upload client 424 425 selects only SARS-CoV-2 sequence reads and discards all human sequences.

120

427 Data availability

- 428 Submitted sequencing reads (free from human reads) for all included samples are
- 429 available from European Nucleotide Archive study accession PRJEB70597.

430

431 **Conflicts of interest**

432 AvG and NW have received grant funding from Sanofi and The Bill and Melinda Gates

433 Foundation. PWF receives consultancy fees from the Ellison Institute of Technology,

434 Oxford. JT, DWC and TEAP receive funding from the Ellison Institute of Technology,

435 Oxford.

436

437 Acknowledgments

- 438 Microbial Genomics Reference Laboratory, New South Wales Health Pathology,
 439 Sydney, Australia
- El Instituto de Salud Pública de Chile, Chile
- Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for
 Communicable Diseases (NICD), a division of the National Health Laboratory
 Service, South Africa
- The Institut Pasteur de Dakar, Senegal
- Oxford University Hospitals NHS Trust, Oxford, United Kingdom
- University of Virginia, Charlottesville, United States of America
- Oxford University Clinical Research Unit, Vietnam
- Hospital for Tropical Diseases SARS-CoV-2 testing team, HTD Vietnam: Le
- 449 Manh Hung, Nguyen Le Nhu Tung, Nguyen Thanh Phong, Vo Minh Quang,
- 450 Pham Thi Ngoc Thoa, Nguyen Thanh Truong, Tran Nguyen Phuong Thao,

- 451 Dao Phuong Linh, Ngo Tan Tai, Ho The Bao, Vo Trong Vuong, Huynh Thi
- 452 Kim Nhung
- Oracle Global Health Business Unit

454 **References**

- Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2.
 Nature. 2021;600(7889):408-18.
- Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, et al. A year of genomic
 surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science. 2021;374(6566):423-31.
- 459 3. McCrone JT, Hill V, Bajaj S, Pena RE, Lambert BC, Inward R, et al. Context-specific emergence and
 460 growth of the SARS-CoV-2 Delta variant. Nature. 2022;610(7930):154-60.
- 461 4. Raghwani J, du Plessis L, McCrone JT, Hill SC, Parag KV, Theze J, et al. Genomic Epidemiology of
 462 Early SARS-CoV-2 Transmission Dynamics, Gujarat, India. Emerg Infect Dis. 2022;28(4):751-8.
- Snell LB, Fisher CL, Taj U, Stirrup O, Merrick B, Alcolea-Medina A, et al. Combined epidemiological
 and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of
 unidentified cases in transmission. Clin Microbiol Infect. 2022;28(1):93-100.
- 466 6. Updated working definitions and primary actions for SARS-Cov-2 variants. WHO Technical
 467 Advisory Group on Virus Evolution; 2023.
- Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and
 clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757-73.
- 470 8. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al. Antibody
 471 escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422-33
 472 e13.
- 473 9. Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, et al. SARS-CoV-2
 474 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical
 475 immunotherapeutics relative to viral variants of concern. EBioMedicine. 2022;84:104270.
- 476 10. Merhi G, Koweyes J, Salloum T, Khoury CA, Haidar S, Tokajian S. SARS-CoV-2 genomic
 477 epidemiology: data and sequencing infrastructure. Future Microbiol. 2022;17:1001-7.
- 478 11. Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, et al. Global disparities in
 479 SARS-CoV-2 genomic surveillance. Nat Commun. 2022;13(1):7003.

480 12. Carter LL, Yu MA, Sacks JA, Barnadas C, Pereyaslov D, Cognat S, et al. Global genomic surveillance
481 strategy for pathogens with pandemic and epidemic potential 2022-2032. Bull World Health Organ.
482 2022;100(4):239-A.

483 13. Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-informed pathogen
484 surveillance in Africa: opportunities and challenges. Lancet Infect Dis. 2021;21(9):e281-e9.

485 14. Chen Z, Azman AS, Chen X, Zou J, Tian Y, Sun R, et al. Global landscape of SARS-CoV-2 genomic
486 surveillance and data sharing. Nat Genet. 2022;54(4):499-507.

487 15. Ohlsen EC, Hawksworth AW, Wong K, Guagliardo SAJ, Fuller JA, Sloan ML, et al. Determining Gaps
488 in Publicly Shared SARS-CoV-2 Genomic Surveillance Data by Analysis of Global Submissions. Emerg
489 Infect Dis. 2022;28(13):S85-S92.

490 16. EIT Pathogena [Available from: <u>https://eit-pathogena.com</u>.

491 17. Constantinides B, Hunt M, Crook DW. Hostile: accurate decontamination of microbial host
492 sequences. Bioinformatics. 2023;39(12).

493 18. Hunt M, Hinrichs AS, Anderson D, Karim L, Dearlove BL, Knaggs J, et al. Addressing pandemic494 wide systematic errors in the SARS-CoV-2 phylogeny. bioRxiv. 2024:2024.04.29.591666.

495 19. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human
496 respiratory disease in China. Nature. 2020;579(7798):265-9.

497 20. Aksamentov I, Roemer C, Hodcroft EB, Neher RB. Nextclade: clade assignment, mutation calling
498 and quality control for viral genomes. Journal of Open Source Software. 2021;6(67):3773.

499 21. O'Toole A, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of

500 epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol.

501 2021;7(2):veab064.

502 22. Mazariegos-Canellas O, Do T, Peto T, Eyre DW, Underwood A, Crook D, et al. BugMat and
503 FindNeighbour: command line and server applications for investigating bacterial relatedness. BMC
504 Bioinformatics. 2017;18(1):477.

505 23. FindNeighbour5 [Available from: <u>https://github.com/oxfordmmm/FN5</u>.

- 506 24. Constantinides B, Webster H, Rodger G, Hunt M, Supasa P, Dejnirattisai W, et al. A diverse
- 507 reference set of cultured SARS-CoV-2 genomes sequenced using various amplification methods and
- 508 instrument platforms 2024 [Available from: <u>https://www.ebi.ac.uk/biostudies/studies/S-BSST1334</u>.
- 509 25. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE
 510 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol Biol Evol.
 511 2020;37(5):1530-4.
- 512 26. Tosta S, Moreno K, Schuab G, Fonseca V, Segovia FMC, Kashima S, et al. Global SARS-CoV-2
 513 genomic surveillance: What we have learned (so far). Infect Genet Evol. 2023;108:105405.
- 514 27. Foulkes S, Monk EJM, Sparkes D, Hettiarachchi N, Milligan ID, Munro K, et al. Early Warning
- 515 Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-September 2022.
- 516 Emerg Infect Dis. 2023;29(1):184-8.
- 517 28. Xu Y, Liu T, Li Y, Wei X, Wang Z, Fang M, et al. Transmission of SARS-CoV-2 Omicron Variant
 518 under a Dynamic Clearance Strategy in Shandong, China. Microbiol Spectr. 2023;11(2):e0463222.
- 519 29. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The evolution of
 520 SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361-79.
- 30. van der Westhuizen HM, Soundararajan S, Berry T, Agus D, Carmona S, Ma P, et al. A consensus
 statement on dual purpose pathogen surveillance systems: The always on approach. PLOS Glob Public
 Health. 2024;4(11):e0003762.
- 524 31. Oude Munnink BB, Worp N, Nieuwenhuijse DF, Sikkema RS, Haagmans B, Fouchier RAM, et al.
 525 The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat Med.
 526 2021;27(9):1518-24.
- 527 32. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of
 528 SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266-9.
- 529